Cytokine gene therapy was studied in established L42 tumour responses. These were due to local release of cytotumours in syngeneic rats. L42 is a transplantable nonkines, not to systemic effects. Growth retardation also immunogenic non-small cell lung cancer (NSCLC). Genes occurred in contralateral tumours which were not injected. coding for human interleukin-1␣ and for rat interleukin-3␤
Introduction
Cytokine gene therapy has been proposed as a promising new approach to immunotherapy of cancer, because of impressive tumour responses in experimental animals. 1, 2 In several studies, implantation of tumour cells genetically engineered to produce cytokines evoked tumourspecific immunity, as evidenced by the rejection of subsequently injected parental cells. Such effects have been observed with transduced cells expressing IL-2, 3, 5 interferon-␥, 6 IL-7, 7 GM-CSF, 8 IL-12 9 and several other cytokines including IL-1 10 and IL-3.
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Fewer reports are available of significant responses of established tumours as a result of treatment with cytokine expressing cells. 12, 13 In another approach, in vivo gene transfer using adenovirus vectors harbouring the IL-2 gene into established tumours has resulted in regression. 14, 15 The introduction of cytokine genes was originally conceived as a means of inducing immunostimulatory signals inside tumours to enhance the host's antitumour immune response. During local inflammation, invading host cells may destroy cells and release tumour antigens in a form that can be presented to T lymphocytes. Accordingly, our focus has been on inducing a strong inflammatory reaction by gene transfer of IL-1 or IL-3.
IL-1 is one of the most pleiotropic cytokines capable of potentiating both specific (humoral and cellular) as well as non-adaptive immune responses. 17, 18 There are two distinct IL-1 genes. Their corresponding proteins, IL-1␣ and IL-1␤ bind to the same cell surface receptor and have identical biological properties. The interspecies similarity is more than 70% for both proteins and cross-species bioactivity was demonstrated. 19 Apte et al 10 reported a direct correlation between the constitutive expression of IL-1␣ and reduced tumorigenicity of a murine fibrosarcoma. They have found that IL-1␣ induces enhanced helper T cell activity which provides auxiliary signals for the development and proliferation of cytotoxic T lymphocytes (CTL). Non-adaptive effector cells, activated locally by IL-1 expressing fibrosarcoma cells, were also shown to contribute to the eradication of the tumours.
The cross-species reactivity of IL-3 is poor. 20 IL-3 exerts a broad spectrum of biological properties, including stimulation of effector functions of monocytes, eosinophils and basophils, which initiate and enhance inflammation and allergic reations. [21] [22] [23] Urticaria-like lesions in the skin as well as arthritis were observed in rhesus monkeys following treatment with high doses of rhesus recombinant IL-3 protein. 24 These lesions contained many mast cells which -if also accumulating in a tumourmight add a new component to inflammatory carcinolysis. Pulaski and colleagues 25 showed that expression of IL-3 in a mouse lung carcinoma inhibits growth by stimulation of CD8
+ lymphocytes through a CD4
+ -dependent mechanism and enhanced expression of major histocompatibility complex (MHC) class I molecules in the transfected tumour cells. Recently, these investigators have demonstrated that IL-3 enhanced CTL development by increasing the number of macrophage-like antigen presenting cells (APC) within the tumour. 26 McBride et al 11 have found that IL-3 was effective in enhancing the immunogenicity of irradiated tumour cell vaccines in a murine fibrosarcoma model. Protection was tumour specific and spleen cells from immunized mice could adoptively transfer immunity. They also found that MHC class I expression is increased on IL-3-transduced tumour cells.
We investigated whether high levels of IL-1 or IL-3 in the tumour would induce regression of established tumours and generate tumour-specific immunity. The tumour employed is a non-immunogenic transplantable rat bronchial carcinoma (L42). In the exploratory phase of our study, we observed regression of tumours following repeated intra-tumour injections of extremely large doses (5 g daily for 10 days) of human IL-1␤, as well as regression of an untreated second tumour growing simultanously in the same rat. Moreover, the cured rats rejected subsequent inoculates of L42 cells. However, systemic toxicity occurred during the treatment with IL-1, and lower doses did not induce tumour responses, suggesting that the bulk of the injected protein was flushed out by the blood circulation. To avoid systemic toxicity and yet maintain high concentrations of the cytokine in the tumour, we have explored adenovirus-mediated gene transfer. L42 tumour cells are relatively permissive to adenovirus as compared with other rat lung tumour cell lines. For logistic reasons we decided to treat the tumours with adenovirus producer cells. For repeated administration to groups of rats, producer cells from multiple cultures were pooled and cryopreserved to be used after thawing -which lysed the cells -for treatment. In the present study, we demonstrate the feasibility of this delivery system to inhibit tumour growth in vivo and to induce systemic immunity against remote tumours.
Results
Cytokine production by L42 cells after in vitro infection with recombinant adenovirus harbouring the hIL-1␣ or rIL-3␤ cDNA The susceptibility of rat bronchial carcinoma cells to infection by adenovirus vectors harbouring the hIL-1␣ or rIL-3␤ cDNA and subsequent levels of cytokine production were determined in vitro.
IL-1␣ production following IG.Ad.MLP.hIL-1␣ infection of L42 cells at different MOI was quantified by ELISA. IL-1␣ does not have a typical NH 2 -terminal hydrophobic secretory signal sequence. Thus, IL-1␣ is not translocated into the endoplasmic reticulum via the classical exocytic secretory pathway. 27 An alternative secretory pathway that requires an intracellular calcium elevation is used. This secretion mechanism is shared by several cells. 28 Therefore, we wanted to know whether L42 cells were capable of secreting IL-1␣ protein. Cytokine production was measured by ELISA in two separate experiments in supernatants and cell lysates 72 h after infection. These data show that IL-1␣ is produced and secreted (20-40%) by the tumour cells upon infection. The bioactivity of the IL-1 protein produced was confirmed in a proliferation assay on D-10 cells as described by Hopkins and Humphries. 29 As an ELISA is not available for rat IL-3, we used a proliferation assay to establish if L42 cells are capable of producing and secreting IL-3. The cells were infected in culture with IG.Ad.CMV.rIL-3␤ virus. Seventy-two hours later, supernatants were tested by limiting dilution for IL-3 activity in a proliferation assay on FDC-P1 cells. The supernatants of three different cultures were tested separately and the standard curve with mouse receiving IL-3 was made in triplicate. In all cases the triplicate dilution versus proliferation curves were closely similar. Supernatants of cells infected with IG.Ad.CMV.Luc virus did not stimulate proliferation, indicating that the activity observed in supernatants of cells infected with IG.Ad.CMV.rIL-3␤ virus was specific for IL-3. As the species specificity of rat IL-3 is not known quantitatively and since the test cells and the standard IL-3 were both of murine origin, one can only derive comparative values from this assay. In supernatants of L42 cells infected at 100 MOI the activity was equivalent to that of 750 U/ml of mouse IL-3. In supernatants of similarly infected human A 549 cells the activity was found to be about 15 times higher, which supports the validity of the assay. The higher transduction of human cells is due to their higher susceptibility to infection by adenovirus vectors as was previously reported. 30, 31 Intra-tumour injection of purified recombinant adenovirus harbouring the IL-1␣ precursor cDNA Established s.c. L42 tumours (n = 5) were injected on day 10 and day 20 after implantation with 10 9 infectious particles of IG.Ad.MLP.hIL-1␣ virus in a volume of 300 l. No effect on the growth rate was observed. This is most likely due to insufficient secretion of cytokines by the transduced cells. The volume at the start of the treatment was about 50 mm 3 (5 × 5 × 5 mm) that is equal to roughly 5 × 10 7 cells. If we consider an ideal situation in which the virus particles are equally distributed over the tumour, the in vivo MOI corresponding to the injection of 10 9 infectious virus particles was about 20. Assuming a linear relation between MOI and cytokine production, we estimate from the in vitro data that between 1 and 2 ng of IL-1 is produced per day in the tumours after the recombinant adenovirus injection. This is about 3000 times less than the IL-1␤ protein dose administered daily in the pilot experiment described above. This estimate does not change much if the more realistic situation of a higher local concentration of virus along the needle track is considered, that is a smaller number of tumour cells being infected with a higher MOI.
Injection of cytokine-adenoproducer cells into L42 tumours
In an attempt to increase the levels of cytokine in the tumours, we decided to inject the tumours with adenoproducer cells. This would result in two sources of cytokine: the 293 cells that produce not only adenovirus vectors but also cytokine until they complete the virus infection cycle and die, and the tumour cells following transduction by the adenovirus vectors, released from the 293 cells.
'Viable' adenoproducer cells were injected into the left (ipsilateral) tumours of rats bearing bilateral s.c. tumours. The producer cells were IG.Ad.MLP.hIL-1␣-293 cells and IG.Ad.MLP.rIL-3␤-293 cells. In control groups, tumours were either not treated or injected (left tumours) with IG.Ad.MLP.LacZ-293 cells or 293 cells. In these pilot experiments 107 adenoproducer cells in a volume of 300 l were injected on days 10 and 30 after implantation. This treatment resulted in growth delay of ipsilateral as well as of contralateral tumours in two of four (IL-1) and three of four (IL-3) rats. Systemic toxicity was not observed and in the control groups tumour growth was not inhibited.
We then attempted to improve the tumour response by increasing the number of administrations. However, the high logistic demands of having available sufficient fresh producer cells at the appropiate time, made us employ 'cracked' adenoproducer cells instead. These are 293 cells that underwent a similar productive virus infection as the 'viable' cells, and thereafter were frozen and stored. Before injection, the cells are thawed, thereby lysed, which results in the release of the cytokine and the recombinant adenovirus. The advantage of using 'cracked' cells is that they can be manufactured at any time and stocked. This allows the treatment of many animals with the same pooled material, excluding influence of variations in virus titres or cytokine concentrations between batches. In addition, the MLP promoter in the IG.Ad.MLP.rIL-3␤ virus was replaced by the stronger CMV promoter (IG.Ad.CMV.rIL-3␤ virus) and used to produce 'cracked' cells.
Samples of 'cracked' adenoproducer cells were characterized for the titre of recombinant adenovirus and for the cytokine concentrations. Samples of IG.Ad.MLP.hIL-1␣-293 producers were used to determine the number of infectious particles contained in 10 7 cells. The range of infectious particles per 10 7 cells was 10 9 -5 × 10 10 (n = 7). In the case of IG.Ad.CMV.rIL-3␤-293 producers, the infectious particles present in 10 7 cells were between 10 The results are depicted in Figure 1 . Note the increase of volume of the tumours injected with 'cracked' adenovirus producer cells, including the ones in the Ad.TK group, during the period that the injections are given. This is likely to be a nonspecific inflammatory reaction.
Thereafter, regression of the treated tumours (partial or complete) and growth delay of contralateral nontreated tumours were observed in the rats injected with the IL-1 'cracked' or the IL-3 'cracked' cells. Statistical analysis revealed no significant difference between untreated controls and Ad.TK (viral) controls. Responses to treatment with Ad.IL-1 and Ad.IL-3 were significant as compared with either of the control groups. The response to Ad.IL-1 was significantly better than to Ad.IL-3.
In the separate analysis of the responses of the injected tumours, the Ad.TK did not differ significantly from the untreated control group. All other comparisons yielded significant differences as in the previous analysis.
The responses of the non-injected tumours when analysed separately were also significant for the Ad.IL-1 and the Ad.IL-3 groups, as compared with either of the control groups, but there was no significance for the difference between the IL-1 and the IL-3 group.
In a separate experiment using the same parameters, tumours were removed for histological examination at 16 and 24 days after implantation, ie 6 and 14 days after initiation of the daily treatment with 'cracked' cells. Control tumours were either not treated or injected with IG.Ad.CMV.TK-293 'cracked' cells.
Histological examination of the ipsilateral (injected) tumours revealed different features in the cytokine groups as compared with the control groups. At day 16, infiltration of the stroma with macrophages, mononuclear cells and granulocytes with foci of necrosis were observed in the tumours injected with the 'cracked' cytokine cells. We could not distinguish a specific predominant cell type in the infiltrates. At day 24, the larger part of the ipsilateral tumour was necrotic. Scar tissue and small areas of living tumour cells were observed ( Figure  2 ). The histological evaluation in the contralateral tumours at day 24 revealed a similar picture as observed in the ipsilateral tumour at day 16, but with less necrosis. There were no distinct histological differences between the IL-1-and the IL-3-treated groups. None of the tumours from the control groups showed significant abnormalities.
To exclude the possibility that the growth inhibition was due to high cytokine levels in the circulation, 'cracked' producer cells were injected s.c. into the left flank for 10 days in the same amounts as described above and the growth of a tumour in the right flank was monitored. The injections were started 10 days after the tumour had been implanted. No difference in growth rate was observed between the cytokine groups and the control groups (Figure 3 ).
Therapeutic vaccination using cell lysates of tumours previously treated with 'cracked' adenoproducer cells In order to explain the response of untreated contralateral tumours following treatment of an ipsilateral tumour with 'cracked' cells, we postulated that liberation of specific tumour antigens takes place in the treated tumours as a result of the inflammation, which initiates a systemic immune reaction against the distant tumour. To test this hypothesis, we designed a therapeutic vaccination using lysates of tumours that were being treated with 'cracked' cells. To prepare the lysates, rats bearing unilateral L42 tumours, received daily injections into the tumour of 'cracked' cells, starting 15 injection) and tumours injected with IG.Ad.CMV.rIL-3␤-293 cells (2.5 × 10 5 cells per injection). Since we did not know what the optimal time-point was at which the assumed release of tumour antigens occurs, two rats of each group were killed at two different time-points during treatment with the 'cracked' cells (after the fourth and eighth injection), and standard pieces of each tumour were frozen. Subsequently, the frozen samples were thawed and minced. Equal amounts of tumour lysates of each treatment group were pooled and used to vaccinate rats bearing established unilateral s.c. L42 tumours (10 days after tumour implantation). The vaccination dose was 6.5 mg of tumour tissue in 0.5 ml of phosphate buffer. The vaccination was done s.c. in the contralateral flank or intraperitoneally (i.p.) at days 10 and 17 after tumour implantation. Each of the different lysates was tested in separate groups of three or four rats each as shown in Figures 4 and 5 , which depict the growth curves of the tumours following vaccination.
The statistical analysis revealed that when the data for both routes of vaccination were taken together, the two control groups did not differ significantly. Ad.IL-1 as well as Ad.IL-3 differed significantly from the untreated controls, but only Ad. IL-3 was different from the viral control Ad.TK. The response of the Ad.IL-3 groups was significantly better than that of the Ad.IL-1 groups.
When the s.c. experiment was analysed separately, both Ad.IL-1 and Ad.IL-3 responded significantly com- 
Figure 3 Growth curves of unilateral L42 tumours of rats that received s.c. injections of 'cracked' adenoproducer cells in the contralateral flank. Tumours were implanted in the right flank of rats (n = 16). At day 10, the animals were divided into four groups (four rats per group). The control group was not treated and groups 2, 3, and 4 received daily s.c. injections in the left flank of various 'cracked' adenoproducer cells for 10 days (*) as shown in the graph. Vertical bars represent standard errors.

Figure 4 Growth curves of unilateral L42 tumours in rats that received s.c. therapeutic vaccination with lysates of tumours treated with 'cracked' adenoproducer cells. Tumour lysates were injected into the contralateral flank of tumour bearing rats on days 10 and 17 after s.c. tumour implantation (arrows). The lysates injected were derived from: (a) untreated tumours; (b) tumours treated with IG.Ad.CMV.TK 'cracked' adenoproducer cells; (c) tumours treated with IG.Ad.MLP.hIL-1␣ 'cracked' adenoproducer cells; (d) tumours treated with IG.Ad.CMV.rIL-3␤ 'cracked' adenoproducer cells.
pared with the control, but in comparison to the viral control (Ad.TK) only the Ad. IL-3 vaccine was significantly effective. If the Ad.IL-1 and the Ad.IL-3 vaccinetreated groups were compared with the combined controls, the differences were significant in both cases.
Within the i.p. set of experiments, the ad.IL-1 vaccine was inactive as compared with either one of the control groups, while the ad. IL-3 vaccine caused a significant growth retardation in comparison to each of the controls. The difference in growth rate between the ad.IL-3 and the ad.IL1-1 groups was also significant. When both control groups were pooled and compared with any of the experimental groups, the results were similar as above.
Taking all data together, there is a significant difference between the s.c. and the i.p. route of vaccination, the former being more effective.
Significant tumour regression and substantial growth delay was observed after s.c. vaccination with either 'IL-1 lysates' or 'IL-3 lysates' (Figure 4) . The i.p. vaccination was effective only in the case of 'IL-3 lysates' ( Figure 5 ).
Discussion
In this study, we explored the potential of the cytokines IL-1␣ and IL-3␤ to trigger a systemic antitumour response. We have been able to induce regression of established s.c. tumours by intra-tumour injections of 'cracked' IL-1␣ and IL-3 adenoproducer cells. The employed tumour is non-immunogenic according to the criterion that vaccination with irradiated cells does not confer protection to a subsequent challenge. Interestingly, we have also observed regression of untreated tumours
Figure 5 Growth curves of unilateral L42 tumours in rats that received i.p. therapeutic vaccination with lysates of tumours treated with 'cracked' adenoproducer cells. Tumour lysates were injected i.p. in tumour bearing rats on days 10 and 17 after s.c. tumour implantation (arrows). The lysates injected were derived from: (a) untreated L42 tumours; (b) tumours treated with IG.Ad.CMV.TK 'cracked' adenoproducer cells; (c) tumours treated with IG.Ad.MLP.hIL-1␣ 'cracked' adenoproducer cells; (d) tumours treated with IG.Ad.CMV.rIL-3␤ 'cracked' adenoproducer cells. Rat killed 126 days after tumour implantation; tumour volume was 5700 mm
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growing at a distant site in the same host animal. This type of reaction seems relevant for the clinical situation, as many patients are diagnosed when the tumour has already metastasized. Intra-tumour injection of recombinant adenovirus harbouring the IL-1␣ cDNA did not affect growth, presumably because the levels of IL-1 achieved were too low. To increase the cytokine production in the tumour, we injected 293 cells producing recombinant adenovirus harbouring the cytokine genes. This treatment resulted in growth delay of a proportion of the tumours. To enable intensification of the treatment we injected 'cracked' adenoproducer cells daily for a period of 10 days and this regimen resulted in more uniform responses. Presumably, the responses were dependent on high concentrations of cytokines inside the tumours. This interpretation is in accordance with results reported by McCune and Marquis, 32 who studied therapeutic vaccination with irradiated lung tumour cells with IL-1 protein as an adjuvant in a syngeneic mouse model. They concluded that the effectiveness of the vaccine depends on the dose and intensity of the IL-1 treatment.
We calculated that the amount of IL-1␣ protein delivered daily to the tumour by the injection of 'cracked' IL-1␣ adenoproducer cells is about 80 ng, but it is unlikely that this will contribute much to the maintenance of significant levels in the microenvironment of the tumour cells, as it will be washed out rapidly by the circulation. The 'cracked' producer cells deliver between 10 9 and 5 × 10 10 recombinant adenovirus infectious particles, which were calculated above to induce the production of between 1 and 50 ng of IL-1 per day by transduced L42 cells. As it is likely that the production continues for several days, daily injections of 'cracked' cells may be expected to lead to a cumulative increase of the cytokine levels inside the tumour, which could well approximate the level attained in our pilot experiment where extremely large amounts of the IL-1␤ protein were injected. With the 'cracked' cells, significant responses were observed without signs of systemic toxicity. However, the regressions were not as complete as in the case of the high dose IL-1␤ protein administration. Clearly, further improvements should be pursued by optimizing the dose and the schedule of injections of 'cracked' cells. The use of 'cracked' adenoproducer cells allows for a rapid read-out of transduction by recombinant viral vectors in vivo, as it saves the effort of downstream processing. Our observation of a significant growth inhibition of established untreated contralateral tumours after treatment of ipsilateral tumours with IL-1␣ or IL-3␤ 'cracked' cells is in accordance with the induction of antitumour immunity by IL-1␣ or IL-3 gene transfer as described by others. 10, 11, 25, 26 We speculate that this growth inhibition is not due to high cytokine levels in the circulation, as it could not be induced by a course of s.c. injections of 'cracked' cells ( Figure 3 ). Of course, these results do not prove that point, because it is not known whether transfected cells of the subcutaneous tissue produce similar amounts of cytokine as transfected tumour cells. Unfortunately, direct measurements of the serum levels of IL-1 and rat IL-3 were not feasible. However, it was pointed out above that in the case of IL-1, the bulk (about 80 ng) is delivered with the 'cracked' cells as preformed protein and it is unlikely that its resorbtion into the blood stream would be less efficient from the s.c. tissue than from the tumour. Furthermore, preliminary experiments comparing intra-tumour injections of 'cracked' cells with injections of equivalent amounts of purified virus show similar tumour responses.
Histological examination revealed that a variety of immune cells (macrophages, mononuclear cells, granulocytes) were recruited to the treated tumours, resulting in necrosis. Apart from a delayed development of the necrosis in the untreated contralateral tumours, we could not identify any differences in the inflammatory reaction in the injected and the contralateral tumours.
The growth delay observed in the distant untreated tumours can only be explained by specific immune reactions. On the basis of studies by others referred to above, we assume that this effect is mediated by the development of cytotoxic T lymphocytes. The experiment in which animals were vaccinated with lysates of tumours treated with 'cracked' cells supports this assumption. We propose that in the first host, the inflammatory reaction induced by IL-1 or IL-3 attracts inflammatory and immune cells to the tumour. Both lysis of tumour cells and release of tumour antigens take place. In the secondvaccinated -host, the tumour antigens contained in the lysate are assumedly suitable for being presented by dendritic cells and thus activate T cells which subsequently act on the distant tumours. In the case of IL-1 lysates, only the s.c. vaccination proved to be effective, while IL-3 lysates elicited tumour regression both after s.c. and i.p. administration. The result of the statistical analysis of these data suggests that the IL-1 vaccine was less potent than the IL-3 vaccine and that the s.c. route of vaccination is more effective than the i.p. route. Additional studies on the mechanism of action of these cytokines are necessary to reveal the differences between the responses to the two vaccines.
In all experiments ( Figures 1, 4 and 5) , regrowth of the tumours was observed 25-30 days following treatment. Only in one animal, after s.c. vaccination with IL-3 lysate, was the relapse delayed for a much longer period, ie 3 months (Figure 4) . The ability of a tumour to escape from immunological control may depend on a balance between the effectiveness of the immune reaction and a variety of factors such as tumour cell proliferation kinetics, immunosuppressive factors (eg TGF-␤, IL-10), tumour-related activation of lymphoid suppressor cells or induction of T cell anergy. 33 Another escape mechanism is the selection of antigen-negative tumour cell variants, as has been described in mice. 34 To conclude, in this study we introduce a new tool for protein-gene delivery by 'cracked' adenoproducer cells. The system seems to be effective for obtaining sufficiently high levels of cytokines inside the tumour for inducing 'inflammatory carcinolysis' resulting in tumour growth delay and to elicit an immune response in the absence of systemic toxicity.
Materials and methods
Reagents and cell lines L42 is a cell line isolated from an undifferentiated bronchial carcinoma that originated in a WAG/Rij rat after implantation of an iodine-125 seed. 35 293 Is a human embryonic kidney cell line expressing adenovirus type 5 (Ad5) E1A and E1B functions. 36 911 Is a human embryonic retina cell line expressing Ad5-E1. 37 A549 Is a human lung carcinoma cell line.
38 L42 cells were cultured in Dulbecco's modified Eagle's medium supplemented with 10% newborn calf serum, non-essential amino acids, penicillin (100 IU/ml; Gibco, Breda, The Netherlands) and streptomycin (50 g/ml; Gibco). 293, A549 and 911 Cells were also cultured in this medium but supplemented with 10% fetal calf serum, non-essential amino acids, penicillin and streptomycin. All cell lines were maintained at 37°C in a humidified atmosphere at 5% CO 2 .
Construction of recombinant plasmids and adenovirus vectors
Human histiocytic lymphoma U937 cells 39 were stimulated for 24 h with 50 ng/ml phorbol myristate acetate (PMA; Sigma Chemical, Bornem, Belgium) to induce synthesis of IL-1 protein. For the isolation and cloning of hIL-1␣ precursor cDNA, RNA was extracted from the stimulated cells, reverse transcribed to make cDNA, which was subjected to PCR analysis using primers specific for human IL-1␣. The sequence of the primers used for PCR analysis were: forward primer: 5Ј-CAGCAAA-GAAGTCAAGATGGCC-3Ј and reverse primer: 5Ј-GTGAGACTCCAGACCTACGCCTGG-3Ј.
The PCR product was ligated directly into pBluescript (Stratagene, Heidelberg, Germany), which was previously digested with SmaI. The resulting clone was named pBS.hIL-1␣. Recombinant adenovirus were plaque isolated twice, propagated, purified by two CsCl density centrifugations, dialyzed and stored in buffer containing 10% glycerol at −80°C. 40 The virus titres were determined by endpoint cytopathogenic effect (CPE) 43 37 using 911 cells.
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Preparation of adenovirus producer cells 293 Cells were cultured in 175 cm 2 flasks (Nunclon, Breda, The Netherlands). At 70-80% confluency, the cells were infected with the recombinant adenoviruses at a MOI of 10. After culturing for 48 h, the infected cells were trypsinized, centrifuged, suspended in PBS and divided into aliquots in different doses as follows: 10 7 cells/300 l for IG.Ad.MLP.IL-1␣ producers, IG.Ad.MLP.LacZ producers, IG.Ad.MLP.rIL-3␤ producers and IG.Ad.CMV.TK producers; 2.5 × 10 5 cells/300 l for IG.Ad.CMV.rIL-3␤. In the experimental protocol of 'viable' adenoproducer cells, the cells were injected into the tumour directly after harvesting. For 'cracked' adenoproducer cells, the aliquots were stored at −20°C and thawed at room temperature before injection. Viable cells were not present in these preparations as judged by Trypan blue dye exclusion and cell culture.
To calculate the amount of infectious particles contained in the adenoproducer cells, 293 cells were lysed by three cycles of freezing/thawing, centrifuged at 6000 r.p.m. for 5 min and the supernatants were used to determine the titre of recombinant adenovirus by end-point CPE 43 in 911 cells. 37 To determine the cytokine contents, the producer cells were sonicated for 45 s and centrifuged at 20 000 g. The supernatants were assayed as follows: for human IL-1␣ both an ELISA (R&D Systems, The Netherlands) and a proliferation assay on D10 cells were used and for rat IL-3␤ a proliferation assay on FDC-P1 cells. 44 Determination of IL-1␣ and IL-3␤ expression in cultured lung tumour cells after recombinant adenovirus infection To determine the IL-1␣ production by L42 cells after infection with IG.Ad.MLP.hIL-1␣ virus, cultured L42 cells suspended at a concentration of 10 5 cells/500 l were infected in duplicate with IG.Ad.MLP.hIL-1␣ at a MOI of 0, 10, 100 and 500. After 2 h of incubation at 37°C in a humidified atmosphere at 5% CO 2 , the cells were washed with PBS and seeded in 24-well culture dishes in 500 l of medium. Seventy-two hours later, supernatants were collected, cells were trypsinized and cell lysates were prepared by sonication for 45 s and centrifugation at 20 000 g for 5 min. The concentration of hIL-1␣ in supernatants and lysates was determinated using the Quantikine ELISA kit (R&D Systems, Minneapolis, MN, USA).
To compare IL-3␤ production after infection of human and rat cells, 2 × 10 5 L42 or A549 cells were seeded in T25 flasks (Nunclon). Twenty-four hours later, the cells were infected with either IG.Ad.CMV.Luc, MOI of 10 (control) or IG.Ad.CMV.rIL-3␤, MOI of 0, 10 and 100. The infection was carried out in a final volume of 2 ml of medium. Seventy-two hours later, supernatants of the infected cells were collected and IL-3 activity was determined in a proliferation assay on FDC-P1 cells. 44 The samples were tested in triplicate.
In vivo protocols
Wag/Rij rats aged 4-6 weeks, weighing 130-150 g, were inoculated s.c. in the shaved flank with 5 × 10 6 L42 cells suspended in 500 l of PBS. After 25-30 days, when the tumour volume was approximately 500 mm 3 , the rats were killed and pieces of approximately 2 × 2 × 2 mm were cut from the viable tumour tissue. The pieces were transplanted s.c. into syngeneic hosts for the performance of the therapeutic experiments. Histological characteristics and biological properties remained constant during successive passages. 45 In the experiments with bilateral tumours, treatment of the left tumour started when the tumour sizes were about 5 × 5 × 5 mm, usually 10 days after implantation. Rats were anaesthetized with ether and the tumours were injected using a 1 ml syringe and a 25-gauge needle. The injected volume was 300 l. To minimize leakage, injections were performed over a period of approximately 30 s. Tumour size was monitored twice a week. The volume of the tumours was derived from measurements of three dimensions a, b and c with vernier calipers using the formula V = abc/6. Animals were killed when the tumour volume was approximately 5000 mm 3 , unless -as happened in some of the bilateral tumour cases -the second tumour was still much smaller. In that situation the animals were kept until the smaller tumour was clearly relapsing.
For histological evaluation, tumours were dissected, cut transversally and fixed in 4% buffered formalin solution, embedded in paraffin, sectioned and stained with haematoxylin and eosin.
Preparation of tumour lysates
Tumour tissue was cut into small pieces with a blender and disrupted in phosphate buffer with a tissue mincer. Total protein in the extracts was determined by Coomassie brillant blue G250 binding with protein assay reagent (Bio-Rad Laboratories, Veenendaal, The Netherlands), based on the Bradford dye-binding procedure. 46 
Statistical analysis
The growth curves were subjected to a three-way analysis of variance on the log of tumour volume, searching for effects of treatment, of tumour location and of time after treatment. In the case of the tumour injection study (Figure 1 ), the first data-point was day 25. In the vaccination study (Figures 5 and 6 ), the first data-point was day 28. By excluding the time-points before the end of treatment -which is the correct thing to do -one also eliminates the problems caused by the measurements during the period of infammatory swelling which occurs after injection with the cytokine vectors. All available data were used for the calculations.
To evaluate differences between individual treatments, and differences in response between treatments for each of the tumour sites (injected and not injected in the case of tumour treatment) the post hoc test of Scheffé was employed. Levels of significance were set at P р 0.05.
